Get the Stockscreener App
218.34
0.85%
-1.88
After Hours:
218.55
0.21
+0.10%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $218.34, with a volume of 4.42M.
It is down -0.85% in the last 24 hours and up +9.92% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
See More
Previous Close:
$220.22
Open:
$219.12
24h Volume:
4.42M
Relative Volume:
0.82
Market Cap:
$385.71B
Revenue:
$58.33B
Net Income/Loss:
$3.73B
P/E Ratio:
103.97
EPS:
2.1
Net Cash Flow:
$18.24B
1W Performance:
+2.72%
1M Performance:
+9.92%
6M Performance:
+2.96%
1Y Performance:
+12.53%
1-Day Range:
$218.22
$220.38
1-Week Range:
$207.61
$221.76
52-Week Range:
$163.81
$221.76
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
218.34 | 373.87B | 58.33B | 3.73B | 18.24B | 2.10 |
|
LLY
Lilly Eli Co
|
755.39 | 676.48B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
178.06 | 423.36B | 90.62B | 22.66B | 18.18B | 9.35 |
|
NVS
Novartis Ag Adr
|
124.12 | 244.98B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
82.81 | 209.89B | 63.43B | 16.42B | 14.72B | 6.49 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
AbbVie Inc. $ABBV Shares Purchased by UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC - MarketBeat
AbbVie Inc. $ABBV Shares Sold by DCM Advisors LLC - MarketBeat
American Trust Reduces Holdings in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Acquired by Woodline Partners LP - MarketBeat
Empowered Funds LLC Acquires 12,448 Shares of AbbVie Inc. $ABBV - MarketBeat
Zurich Insurance Group Ltd FI Has $123.82 Million Stake in AbbVie Inc. $ABBV - MarketBeat
Jones Financial Companies Lllp Sells 141,991 Shares of AbbVie Inc. $ABBV - MarketBeat
Logan Capital Management Inc. Has $23.91 Million Stock Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Can't Halt Miss. Discount Drug Law, 5th Circ. Says - Law360
AbbVie (ABBV) Shares Cross 3% Yield Mark - Nasdaq
AbbVie Loses Latest Bid to Block Mississippi Drug Discount Law - Bloomberg Law News
Best Pharmaceutical Stocks To ConsiderSeptember 11th - MarketBeat
AbbVie Shares Hit Record High on Rinvoq Exclusivity Extension to 2037 - GuruFocus
Promising Biotech Stocks To Keep An Eye OnSeptember 11th - MarketBeat
1 Green Flag for AbbVie (ABBV) Stock Right Now - The Motley Fool
1 Green Flag for AbbVie (ABBV) Stock Right Now - Nasdaq
AbbVie (NYSE:ABBV) Sets New 1-Year HighHere's Why - MarketBeat
AbbVie Stock Hit a Record on ‘Big Win’ for Blockbuster Drug. The Case for Buying In. - Barron's
AbbVie Settles Rinvoq Patent Dispute: What It Means for the Stock - Yahoo Finance
AbbVie extends Rinvoq exclusivity by four years after generics settlements - Yahoo Finance
Intrua Financial LLC Sells 1,688 Shares of AbbVie Inc. $ABBV - MarketBeat
Strs Ohio Invests $158.73 Million in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV is Advisors Capital Management LLC's 4th Largest Position - MarketBeat
BMO Capital Adjusts Price Target on AbbVie to $240 From $215, Maintains Outperform Rating - MarketScreener
Wells Fargo Adjusts Price Target on AbbVie to $260 From $240, Maintains Overweight Rating - MarketScreener
AbbVie settles Rinvoq patent disputes, pushing back generics to 2037 - The Pharma Letter
Acadian Asset Management LLC Has $29.90 Million Stock Position in AbbVie Inc. $ABBV - MarketBeat
Competitiveness Wins if IRS Accepts Tax Court Ruling in AbbVie - Bloomberg Law News
Dynamic Technology Lab Private Ltd Acquires New Holdings in AbbVie Inc. $ABBV - MarketBeat
Voleon Capital Management LP Sells 3,011 Shares of AbbVie Inc. $ABBV - MarketBeat
Meiji Yasuda Asset Management Co Ltd. Sells 31,981 Shares of AbbVie Inc. $ABBV - MarketBeat
Hamilton Capital LLC Sells 1,209 Shares of AbbVie Inc. $ABBV - MarketBeat
Ascent Group LLC Has $5.15 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
RNC Capital Management LLC Sells 3,361 Shares of AbbVie Inc. $ABBV - MarketBeat
Coppell Advisory Solutions LLC Acquires 1,244 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Stock Touches Record High After Company Dismisses Generic Competition For Rinvoq Till 2037: Wells Fargo Terms It A ‘Big Win’ - Stocktwits
AbbVie Logs Best Day In Over 7 Months As Wall Street Cheers Rinvoq Patent Deal Pushing Generics To 2037 - Stocktwits
AbbVie (NYSE:ABBV) Trading Down 1%What's Next? - MarketBeat
Peloton Wealth Strategists Sells 7,000 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Stock Breaks Out As Its Cash Cow Lives To Fight Another Day - Investor's Business Daily
AbbVie shares hit record high as key immunology drug set for exclusivity until 2037 - Reuters
One of AbbVie's key drugs gains protection from generic competition for more than a decade - Crain's Chicago Business
AbbVie shares rise with extension of RINVOQ patent protection to 2037 - Proactive financial news
AbbVie in Settlement With Generic Drugmakers on Rinvoq - The Wall Street Journal
Why AbbVie (ABBV) Stock Is Trading Up Today - Yahoo Finance
Why AbbVie Stock Is Jumping Today - Yahoo Finance
AbbVie lifted by lengthy delay to generics of Rinvoq - pharmaphorum
AbbVie’s Rinvoq Franchise Secures Extended Exclusivity, Boosting Long-Term Prospects and Justifying Buy Rating - TipRanks
‘Really Long Runway’: AbbVie Stock (ABBV) Jumps afer Settlement on Anti-Inflammatory Drug - TipRanks
Market movers: Opendoor, Centene, Delta, AbbVie, Sandisk... - Proactive financial news
AbbVie stock rises after securing patent protection for RINVOQ until 2037 - Investing.com Canada
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.25%
1.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):